Your browser doesn't support javascript.
loading
Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE.
Thariat, J; Schouman, T; Brouchet, A; Sarini, J; Miller, R C; Reychler, H; Ray-Coquard, I; Italiano, A; Verite, C; Sohawon, S; Bompas, E; Dassonville, O; Salas, S; Aldabbagh, K; Maingon, P; de La MotteRouge, T; Kurtz, J E; Usseglio, J; Kerbrat, P; Raoul, G; Lotz, J P; Bar-Sela, G; Brugières, L; Chaigneau, L; Saada, E; Odin, G; Marcy, P Y; Thyss, A; Julieron, M.
Afiliação
  • Thariat J; Department of Radiation Oncology, Cancer Center Antoine-Lacassagne, Institut Universitaire de la Face et du Cou, University Nice Sophia-Antipolis, 06189- Nice Cedex 2, France. jthariat@hotmail.com
Ann Oncol ; 24(3): 824-31, 2013 Mar.
Article em En | MEDLINE | ID: mdl-23131392
ABSTRACT

BACKGROUND:

Mandibular osteosarcomas (MOS) mostly affect young adults. Their treatment is extrapolated from that of extragnathic osteosarcomas. MATERIAL AND

METHODS:

A retrospective multicooperative group study was conducted to determine the impact of chemotherapy, adjuvant radiation therapy and surgery on outcomes and to identify prognostic factors. This ethical committee-approved study included a centralized review of histology slides and operative reports.

RESULTS:

Of 111 patients, 58.6% were male, median age 35 years (13%, ≤18 years). Histology was osteoblastic, chondroblastic, fibroblastic, conventional not otherwise specified and others in 39.6%, 30.6%, 8.1%, 12.6% and 8.0%, respectively. Pathological World Health Organisation grades were low, intermediate and high grade in 6.4%, 11.8% and 81.8%, respectively. Surgery was carried out for 94.5% of patients. Neoadjuvant chemotherapy (mixed protocols) was carried out in 93.1% of patients. Postoperative chemotherapy and radiotherapy were carried out in 54.7% and 23.8%, respectively. Median follow-up was 59.6 months (range). Five-year local control, metastasis-free, disease-free and overall survival rates were 64.6%, 68.9%, 53.2% and 69.2%, respectively. Survival was significantly associated with age, tumor size and surgery. Wide surgery with clear margins and free flap reconstruction was the strongest prognostic factor. Neoadjuvant chemotherapy improved disease-free and metastatic-free survival and increased clear margins rates from 50% to 68%. Intermediate grades behaved like high grades in terms of metastatic-free and disease-free survival.

CONCLUSION:

This homogeneous series is the largest to date and emphasizes the major impact of clear margins and multidisciplinary management. Neoadjuvant chemotherapy improves disease-free survival and should be recommended for both high and intermediate grade MOS.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Mandibulares / Osteossarcoma / Gerenciamento Clínico / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Mandibulares / Osteossarcoma / Gerenciamento Clínico / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2013 Tipo de documento: Article